Current portfolio

Karo Healthcare

A leading consumer healthcare company in the Nordics

Karo Healthcare develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.

  • Sector
  • Country
  • Responsible Advisor
    Erika Henriksson
  • Fund
  • Entry
  • Web

Private Capital

Karo Healthcare


About Karo Healthcare
Karo Healthcare sells and markets a portfolio of everyday healthcare products that help prevent illnesses and treat health problems. The portfolio consists of original brands with strong market positions and comprises both prescription drugs (Rx) as well as consumer products (OTC) within seven distinct categories - Skin Health, Intimate Health, Digestive Health, Foot Health, Wellness, Pain, Cough & Cold and Specialty products. Karo Healthcare's products have a strong position in the Nordic regions and the company has successfully expanded its direct distributions network to several other countries in Western Europe both through organic growth and acquisitions. Overall, Karo Healthcare's products are sold to sixty different markets worldwide. Karo Healthcare was founded in 1987 and is headquartered in Stockholm, Sweden.

Market trends and drivers
The large specialty pharmaceutical market demonstrates stable growth over the cycles and high resilience during economic downturns. The market offers attractive growth opportunities, both organically driven by underlying patient-critical demand, and inorganically through a generally high M&A activity as a result of the continued consolidation in the pharmaceutical industry.

Investment potential
Accelerate organic growth in existing portfolio through commerical and digital focus, primarily on larger "Hero" brands with international presence and potential. Continue consolidating the fragmented speciality pharma and consumer health market by acquiring pan-European brands in core categories with growth potential, targeting attractive organic growth outlook at exit. Increase share of OTC in the overall portfolio. Drive operational improvements including increasing gross margin through CMO and logistics consolidation, as well as driving operating leverage while strengthening Karo Healthcare's organization and capabilities.

Board of directors

  • Chairperson
    Kåre Schultz
  • Board member
    Pat Smallcombe
  • Board member
    Erika Henriksson
  • Board member
    Uta Kemmerich-Keil
  • Board member
    Mark Keatley
  • Board member
    Claire Hennah


  • CEO
    Christoffer Lorenzen
  • CFO
    Jon Johnsson
EQT logo